Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2021 - 2025)

ARS Pharmaceuticals' Other Working Capital Changes history spans 5 years, with the latest figure at -$284000.0 for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 103.92% year-over-year to -$284000.0; the TTM value through Dec 2025 reached -$656000.0, down 110.6%, while the annual FY2025 figure was -$656000.0, 110.6% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$284000.0 at ARS Pharmaceuticals, up from -$1.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $7.3 million in Q4 2024 and bottomed at -$3.1 million in Q4 2021.
  • The 5-year median for Other Working Capital Changes is -$364500.0 (2023), against an average of $59833.3.
  • The largest annual shift saw Other Working Capital Changes plummeted 1327.78% in 2022 before it surged 230.13% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$3.1 million in 2021, then surged by 180.32% to $2.5 million in 2022, then crashed by 207.59% to -$2.7 million in 2023, then skyrocketed by 369.35% to $7.3 million in 2024, then tumbled by 103.92% to -$284000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Other Working Capital Changes are -$284000.0 (Q4 2025), -$1.1 million (Q3 2025), and $907000.0 (Q2 2025).